Wantanee Phuapradit

This inventor holds 57 USPTO granted patents and 21 published patent applications, plus 10 CIPO patents and 9 EPO patents, primarily in Pharmaceutical Compositions (CPC class A61K). Top assignees: Kashiv Biosciences, LLC, Amneal Complex Products Research LLC, Hoffmann-La Roche Inc.. Active years: 1995-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wantanee Phuapradit. Retrieved from https://idiyas.com/inventor/wantanee-phuapradit

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 57 (Patent Applications = 21)

% Patents Active = 94.7

CIPO Patents = 10 (Patent Applications = 10)

EPO Patents = 9 (Patent Applications = 11)

Average Co-Inventor Count = 5.3

ph-index = 6

Forward Citations = 480(Granted Patents)

Forward Citations (Not Self Cited) = 427(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Kearny, NJ (US) (1995 - 1996)
Jersey City, NJ (US) (2000)
Clifton, NJ (US) (2002 - 2006)
Montville, NJ (US) (2010 - 2024)
Lewes, DE (US) (2022 - 2024)

Company Filing History:

13 out of 24

Kashiv Biosciences, LLC

patents

12 out of 13

Amneal Complex Products Research LLC

patents

10 out of 5,026

Hoffmann-La Roche Inc.

patents

4. 10 out of 10

Kashiv Specialty Pharmaceuticals, LLC

Emisphere Technologies, Inc.

8. 4 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2025

Loading Chart...

Areas of Expertise:

Gastroretentive Forms

Sustained Release

Drug Delivery Systems

Programmable Compositions

Pyridostigmine

Liothyronine

Trihexyphenidyl

Abuse-Resistant Formulations

Chrono Drug Release

Osmotic Systems

Methylphenidate

Atopic Dermatitis

57 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12233166 - Extended release compositions comprising pyridostigmine (2025-02-25),

2. 12042559 - Gastroretentive dosage forms for sustained drug delivery (2024-07-23),

3. 12036224 - Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient (2024-07-16),

4. 11964048 - Sustained release compositions comprising liothyronine (2024-04-23),

5. 11911515 - Extended release compositions comprising pyridostigmine (2024-02-27),

6. 11793747 - Self-regulating osmotic gastroretentive drug delivery systems (2023-10-24),

7. 11666536 - Extended release compositions comprising pyridostigmine (2023-06-06),

8. 11564888 - Extended release compositions comprising trihexyphenidyl (2023-01-31),

9. 11547670 - Delayed release methylphenidate compositions (2023-01-10),

10. 11478425 - Extended release compositions comprising pyridostigmine (2022-10-25),

11. 11464742 - Extended release compositions comprising trihexyphenidyl (2022-10-11),

12. 11439585 - Programmable pharmaceutical compositions for chrono drug release (2022-09-13),

13. 11419813 - Programmable pharmaceutical compositions for chrono drug release (2022-08-23),

14. 11318091 - Gastroretentive dosage forms for sustained drug delivery (2022-05-03),

15. 11229606 - Extended release compositions comprising pyridostigmine (2022-01-25),

**Title: Innovations by Wantanee Phuapradit: Pioneering Extended Release Compositions**

Introduction

Wantanee Phuapradit is an accomplished inventor based in Montville, NJ, known for his significant contributions to the field of pharmacology. With an impressive portfolio of 58 patents, he has been at the forefront of developing innovative drug delivery systems that enhance patient compliance and therapeutic efficacy.

Latest Patents

Among his recent inventions, Wantanee's patents cover extended release compositions consisting of pyridostigmine. These formulations are designed to maintain stable plasma concentrations while minimizing initial burst release and dose dumping. His dosage forms include matrix tablets, gastroretentive tablets, and pellets that can be conveniently dosed in capsules, tablets, or mixed with foodstuffs. The innovative methods detailed in these patents aim to improve patient adherence by offering once-a-day extended-release dosage forms of pyridostigmine bromide, ensuring superior controlled drug release. Another notable patent focuses on floating gastroretentive dosage forms that prolong gastric residence time, combined with rapidly expanding sustained release formulations for targeted drug delivery in the proximal gastrointestinal tract, ultimately maximizing therapeutic benefits.

Career Highlights

Throughout his career, Wantanee Phuapradit has collaborated with leading organizations in the pharmaceutical sector, such as Kashiv Biosciences and Amneal Complex Products Research. His extensive work experience underlines his commitment to advancing drug delivery technologies and improving patient outcomes.

Collaborations

In his professional journey, Wantanee has partnered with notable colleagues, including Navnit Hargovindas Shah and Dipen Desai. These collaborations have further enhanced the impact of his research and innovations in the field of pharmaceuticals.

Conclusion

Wantanee Phuapradit exemplifies the spirit of innovation within the pharmaceutical industry. His groundbreaking patents in extended release formulations represent a significant advancement in drug delivery systems, demonstrating the potential to improve patient adherence and therapeutic effectiveness. As he continues to push the boundaries of medical science, Wantanee remains a key figure in the evolution of pharmacological inventions.

Profile summary based on public USPTO records.